Biomedical subjects

Marta I Rendon

Publications and source records attributed to Marta I Rendon.

4 recordsLinked to original sources

PubMed2006

Use of sculptra mark in esthetic rejuvenation.

The addition of Sculptra to the esthetic dermatology landscape in September 2004 brought a new opportunity for facial rejuvenation. Sculptra, which is polymerized lactic acid (PLA), received approval from the Food and Drug Administration for the treatment of HIV-associated lipoatrophy. Since its approval, it has gained acceptance among cosmetic dermatologists and plastic surgeons, and its inclusion in any update of esthetic dermatology is certainly warranted. Its uses for esthetic indications are now being substantiated by clinical trials and, as experience with this product increases, it is likely that it will be more widely used for these reasons.

Biocompatible Materials↗

PubMed2006

Postinflammatory hyperpigmentation: evolving combination treatment strategies.

Postinflammatory hyperpigmentation (PIH) is a common acquired excess of pigment in the epidermal and/or dermal layers of the skin. Lesions persist for extended periods if untreated, thus therapy is warranted. Topical monotherapies include the standard bleaching agent hydroquinone (HQ) as well as retinoids. Recently, several fixed-dose combination products were introduced to the armamentarium: HQ 4%-retinol 0.15% in a microsponge formulation; HQ 4%-retinol 0.3%; mequinol 2%-tretinoin (RA) 0.01%; and fluocinolone acetonide (FA) 0.01%, HQ 4%, and RA 0.05%. Recent findings have suggested that mequinol 2%-RA 0.01% solution is a promising alternative for the treatment of PIH.

Adolescent↗

PubMed2005

Review of skin-lightening agents.

BACKGROUND: Multiple agents are available for the treatment of hyperpigmentation, a cosmetically important condition seen most often in middle-aged and elderly individuals and resulting from exposure to ultraviolet light, certain drugs or chemicals, or the existence of disease. Many skin-lightening agents cause skin irritation and require months of use before results appear, and some agents are only partly effective. OBJECTIVE: To help dermatologists make an informed decision when choosing a depigmenting agent. METHODS: A review of all depigmenting agents used alone and in combination, including its natural properties and information about safety, efficacy, and optimal dosing. CONCLUSIONS: The speed of efficacy and type and extent of side effects vary greatly among depigmenting agents. Knowing the properties associated with each agent enables a physician to choose a product that will best meet a patient's expectations and minimize adverse reactions.

Administration, Topical↗

PubMedDate not supplied

Utilizing combination therapy to optimize melasma outcomes.

Melasma is a chronic and recurrent disorder. It has been underdiagnosed and undertreated due to lack of effective therapies and the perception that it is merely a cosmetic nuisance. Hydroquinone, corticosteroids, licorice extracts and kojic acid have been used as monotherapy to treat melasma. However, the present standard of care in melasma therapy is combination therapy. To date, the most effective treatment is a triple-combination agent that contains hydroquinone 4%, tretinoin 0.05% and fluocinolone acetonide 0.01%. In clinical trials, its use led to complete or near-complete clearing of melasma in 8 weeks. A long-term study demonstrated its continuing efficacy and safety for as long as 360 days. In an examination of quality of life parameters, patients using the triple-combination cream showed significant improvements in self-perception by all 1290 patients. Various combinations of melasma therapy, such as chemical peels, particularly as adjuvants to the triple-combination cream, are discussed.

Administration, Cutaneous↗